Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Canopy Growth's gross profit for the
three
months ended in Jun. 2026 was $15.8 Mil. Canopy Growth's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $53.3 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Canopy Growth's gross profit for the
three
months ended in Jun. 2026 was $15.8 Mil. Canopy Growth's Revenue for the
three
months ended in Jun. 2026 was $57.8 Mil. Therefore, Canopy Growth's Gross Margin % for the quarter that ended in Jun. 2026 was 27.40%.
Canopy Growth had a gross margin of 27.40% for the quarter that ended in Jun. 2026 => Competition eroding margins
During the past 13 years, the highestGross Margin % of Canopy Growth was 97.04%. The lowest was -39.40%. And the median was 18.48%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Canopy Growth had a gross margin of 27.40% for the quarter that ended in Jun. 2026 => Competition eroding margins
Canopy Growth Gross Profit Related Terms
Canopy Growth Gross Profit Historical Data
* Premium members only.
The historical data trend for Canopy Growth's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's Gross Profit distribution charts can be found below:
* The bar in red indicates where Canopy Growth's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $53.3 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Canopy Growth (CGC) has a Gross Profit of $53.3 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Canopy Growth and its competitors.
Is Canopy Growth's Gross Profit too high?
Canopy Growth's current Gross Profit is $53.3 Mil. Overall, Canopy Growth has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's Gross Profit compare to ZTS?
Canopy Growth's Gross Profit of $53.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Canopy Growth and its competitors. Canopy Growth's current Gross Profit is $53.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (CGC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $0.99 — trading 47.5% above its estimated fair value. The current Gross Profit is $53.3 Mil. Canopy Growth's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Canopy Growth (CGC), the current Gross Profit is $53.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (CGC) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of $0.99 is trading 47.5% above its estimated GF Value™ of $0.67.
GuruFocus considers Canopy Growth to be Significantly Overvalued.
Key valuation signals for CGC:
Gross Profit: $53.3 Mil
GF Value™: $0.67 vs. price of $0.99 (47.5% above fair value)
No single metric tells the full story. See the CGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
40GF Score
Get the complete analysis for CGC
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGC has been successfully added to your 
